Featured
Want to learn more about 8th-European-Conference-on-Rare-Diseases-Orphan-Products? You've come to the right site!
Comité del programa
-
Wills Hughes-Wilson Senior Vice President Patient Access & External Affairs, Chief Patient Access Of
Swedish Orphan Biovitrum AB, Sweden -
Alastair Kent, MHS Co-Chair of the UK Rare Disease Policy Board; Former Executive Director
Genetic Alliance UK, United Kingdom -
Bruno Sepodes, PHARMD, PHD, MPH, MSC Vice-Chair CHMP (EMA); Senior Expert INFARMED
INFARMED, Portugal -
Christian Cottet Chief Executive Officer
AFM - Assoc. Française Contre Les Myopathies, France -
Dorica Dan President
Romanian National Alliance for Rare Diseases, Romania -
Pascal Garel Chief Execuitve
HOPE - European Hospital and Healthcare Federation, Belgium -
Adam Heathfield, PHD Senior Director, Global Access and Value
Pfizer Inc, United Kingdom -
Veronique Heon-Klin
The Federal Ministry of Health, Germany -
Edmund Jessop, DrMed Medical adviser at NHS England
National Health Service, United Kingdom -
Helena Kääriäinen Research Professor
National Institute for Health and Welfare, Finland -
Kristina Larsson, MS Head of Orphan Medicines, Division for Human Medicines Evidence Generation
European Medicines Agency, Netherlands -
Yann Le Cam, MBA Chief Executive Officer
Eurordis-Rare Diseases Europe, France -
Jordi Llinares Garcia, MS Head of Research and Innovation
European Medicines Agency, Netherlands -
Flaminia Macchia Director
Vertex Pharmaceuticals (france) SAS, France -
Kay Parkinson, JD Director
Alstrom Syndrome Europe (AS EU), United Kingdom -
Vinciane Pirard, MD Senior Director Public Affairs (Europe & International)
Sanofi-Genzyme, Belgium -
Gayatri R. Rao, JD, MD
Rocket Pharmaceuticals, Inc., United States -
Ana Rath Managing Editor
Orphanet-Inserm, France -
Miriam Schlangen
Namse Geschäftsstelle, Germany -
Domenica Taruscio Director
National Center for Rare Diseases, Italy -
Till Voigtländer Clinical Institute of Neurology
University of Vienna, Austria
¿Tiene una cuenta?